Craig Venter’s legacy: from decoding the genome to creating synthetic life

The recent death of J. Craig Venter prompts a reflection on the legacy of one of the most influential figures in the contemporary genomics revolution. From the intense scientific rivalry that marked the Human Genome Project to the development of synthetic biology, his career epitomizes the shift from deciphering life to attempting to design it. This article traces the defining moments of his scientific and business legacy, while considering the profound ethical, philosophical, and technological implications that emerge from a new way of understanding life as a programmable system.

A year ago we published an article on the Bioethics Observatory website commemorating the 25^th anniversary of the completion of the first step towards one of the greatest milestones in the history of science: the initial draft of the Human Genome Project (HGP).

That announcement took place on June 26, 2000, in a session chaired by then-US President Bill Clinton and former British Prime Minister Tony Blair (who spoke via satellite). The event was attended by the project’s two chief architects, Francis Collins and J. Craig Venter, who had been racing to decipher the genetic information contained in the DNA of our genome using different approaches.

On April 29, the J. Craig Venter Institute (JCVI) in La Jolla, California, announced the death in San Diego of one of the major figures behind that monumental scientific and technological breakthrough, the American biologist and businessman J. Craig Venter (1946-2026), founder and president of the JCVI. His passing followed a brief hospitalization due to unexpected side effects that arose from treatment of recently diagnosed cancer.

Dr. Venter’s outstanding qualities as a researcher were amply demonstrated in the aforementioned project and in his subsequent ventures into “Synthetic Biology”, of which he was considered its foremost proponent. He was a maverick scientist, innovative, ambitious, brilliant and with immense confidence and self-assurance. At the 2000 White House event, in front of those who argued that sequencing the human genome could strip life of its mystery, he countered that: “Nothing could be further from the truth…The complexities and wonder of how the inanimate chemicals that are our genetic code give rise to the imponderables of the human spirit should keep poets and philosophers inspired for the millennium.”

His entrepreneurial spirit and boldness in tackling the great questions of life have had a profound impact on the development of contemporary synthetic biology.

From sequencing the genome to the race to decode it

The HGP was planned in two stages, the first being to obtain a draft of the genome, a goal that was achieved in 2001. It is important to note that the project was fuelled by the competition between two differing strategies.

On the one side, the slower and more costly public strategy was to sequence the entire genome chromosome by chromosome. The project was initially led by James Watson (1928-2025)—winner of the Nobel Prize in Physiology or Medicine for the discovery of the structure of DNA—before leadership passed to Francis Collins (b. 1950) at the helm of a well-resourced international consortium endorsed by the US National Institutes of Health.^[1]

On the other side, the private strategy led by Craig Venter from Celera Genomics (a company he launched) proposed a faster alternative using high-throughput sequencing and the use of expressed sequence tags (EST), focusing on coding regions of DNA derived from messenger RNA. This method enabled rapid identification of large numbers of human genes and accelerated genome mapping efforts.^[2] This approach to the HGP also had the advantage of simultaneously providing insights into the structure and function of genes. Venter and his team later published the first high-quality diploid human genome, underlining the importance of capturing genetic variation inherited from both parents.^[3] This approach helped transform genomics into a data-driven, scalable, and systematic science, laying the groundwork for subsequent genome engineering.

In this sense, Venter was a visionary, helping to transform genomics from a slow, gene-by-gene discovery process to a scalable, data-driven science, to eventually demonstrate that genomes could even be designed and built from the bottom up.

Venter was awarded the Prince of Asturias Award for Technical and Scientific Research in 2001, together with the Americans Francis Collins (b. 1950) and Hamilton Smith (1931-2025), Englishman John Sulston (1942-2018), and Frenchman Jean Weissenbach (b. 1946), all of them prominent molecular biologists responsible for our understanding of genomic organization and mapping the human genome.

In a 1999 article published in the journal Science, Venter stated that: “What is life? I don’t think there are that many biologists trying to answer that one… We’re… working on a reductionist view of trying to take the smallest genome that we have… and see if we can’t understand how those… [genes] work together to create life.” This idea paved the way for the possibility that, over time, genomes could be designed and synthesized.

Life as a programmable system: the leap towards synthetic biology

In 2005, together with Nobel laureate Hamilton O. Smith, Venter founded Synthetic Genomics Inc., a company that would merge genomics and synthetic biology to address problems in industry and medicine. This work culminated in 2010 with an historic achievement: the creation of the first self-replicating synthetic genome. The team synthesized the genome of the bacterium Mycoplasma mycoides, base by base, piece by piece, and implanted this genome into Mycoplasma capricolum cells, thereby generating a cell controlled by synthetic DNA.^[4]

This breakthrough was a demonstration of immense technological significance, with potential applications in synthetic biology, energy, the environment and personalized medicine. However, it also ignited a fierce ethical debate on the limits of manipulating life, biosecurity, and governance of these emerging technologies ^[5].

Venter himself argued that these advances should be directed towards societal benefits, although his view clearly reflected the reductionist approach of synthetic biology: “DNA is the software of the cell… Because it is based on the digitized DNA sequence, the design of synthetic genomes provides a true interface between the computer and biological life.” Venter believed genomes could be designed and built.

Another important milestone in his career was the Sorcerer II Global Ocean Sampling Expedition, an ambitious marine metagenomics project that enabled the analysis of microbial biodiversity in nature, in marine surface water samples. This study presented a new comparative genomic method, termed “fragment recruitment”, which allowed the discovery of millions of new genes. It also greatly expanded our understanding of genetic diversity, evolution and adaptation of microorganisms in natural ecosystems, as well as numerous changes in gene content, and the development of microorganisms in natural ecosystems, some with direct adaptive implications.^[6]

In addition to his scientific work, Venter stood out as an entrepreneur and a driving force behind key institutions. As well as Celera Genomics, the JCVI and Synthetic Genomics, Inc., he also founded Human Longevity Inc. and Diploid Genomics Inc., aimed at translating genomic advances into benefits for health, the environment and society.

In 2010, a letter by then-President Barack Obama called on the Presidential Commission for the Study of Bioethical Issues to examine the benefits and risks of synthetic biology, in which he mentioned “…the potential medical, environmental, security, and other benefits of this field of research, as well as any potential health, security or other risks”. This call for reflection remains fully applicable in a context where technologies such as gene editing and artificial intelligence further expand the possibilities—and responsibilities—of bioscience.

In summary, the figure of J. Craig Venter represents a key transition in modern biology: from decoding the genome to its design and synthesis. His legacy lies not only in the technical advances achieved, but also in having fostered a new way of understanding life as a programmable system, opening up scientific, philosophical and ethical questions that will continue to shape the future.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

References:

[1] The International Human Genome Mapping Consortium. “A physical map of the human genome”. Nature 409 (2001) 934-941

[2] The Celera Genomics Sequencing Team. “The sequence of the human genome”. Science (2001) 1304-1351

[3] Mayor, S. “Genome sequence of one individual is published for first time”. BMJ 335(7619) (2007) 530-531

[4] Gibson, D.G., Glass, J.I., Lartigue, C., Venter, J.C. et al. “Creation of a bacterial cell controlled by a chemically synthesized genome”. Science. 329(5987) (2010) 52-56

[5] Cho, M.K., Magnus, D., Caplan, A.L., McGee, D. “Ethical Considerations in Synthesizing a Minimal Genome”. Science, 286 (1999) 2087-2090

[6] Rusch, D.B., Halpern, A.L., Sutton, G., Venter, J.C. et al. “The Sorcerer II Global Ocean Sampling expedition: northwest Atlantic through eastern tropical Pacific”. PLoS Biol. 5(3) (2007) e77